Chromosome 15q11.2 microdeletion is an emerging syndrome identified in individuals with Prader‐Willi syndrome and Angelman syndrome but also found in isolation. Here, the authors present a case of a 19‐year‐old woman with chromosome 15q11.2 microdeletion and her successful treatment with risperidone, a tailored positive behaviour support plan and with staff training around non‐epileptic attack disorder.
{"title":"Risperidone in non‐epileptic attack disorder and chromosome 15q deletion syndrome","authors":"A. Javaid, David Kent, Joanne Bone, D. Michael","doi":"10.1002/pnp.725","DOIUrl":"https://doi.org/10.1002/pnp.725","url":null,"abstract":"Chromosome 15q11.2 microdeletion is an emerging syndrome identified in individuals with Prader‐Willi syndrome and Angelman syndrome but also found in isolation. Here, the authors present a case of a 19‐year‐old woman with chromosome 15q11.2 microdeletion and her successful treatment with risperidone, a tailored positive behaviour support plan and with staff training around non‐epileptic attack disorder.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47865478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.
{"title":"Melatonin as first‐line treatment for sleep disorders in Parkinson's disease?","authors":"C. Cox, A. Mackett","doi":"10.1002/pnp.728","DOIUrl":"https://doi.org/10.1002/pnp.728","url":null,"abstract":"Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47021974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Electroconvulsive therapy (ECT) is used in Huntington's disease (HD) for severe and life threatening forms of mental illness when other treatment options have failed or when a rapid response is required. Here, Dr Yahya and Dr Khawaja review the published literature over the last 10 years for the use of ECT in HD focusing on efficacy, safety and tolerability.
{"title":"Electroconvulsive therapy in Huntington's disease","authors":"A. Yahya, Shakil Khawaja","doi":"10.1002/pnp.729","DOIUrl":"https://doi.org/10.1002/pnp.729","url":null,"abstract":"Electroconvulsive therapy (ECT) is used in Huntington's disease (HD) for severe and life threatening forms of mental illness when other treatment options have failed or when a rapid response is required. Here, Dr Yahya and Dr Khawaja review the published literature over the last 10 years for the use of ECT in HD focusing on efficacy, safety and tolerability.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45011867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Roberts, Nittu Sidhu, Melanie Russel, Mohammed Abbas
Vaccines are the predominant biological management measure for controlling the COVID‐19 pandemic, and aim to break the chain between disease status and hospitalisation. Unseen or rare side‐effects are being reported via the COVID‐19‐specific Yellow Card reporting site, including mania, psychosis and encephalitis of various subtypes. This article presents a patient displaying a range of psychiatric pathologies that occurred within 10 days of AstraZeneca COVID‐19 vaccination and resolved spontaneously without antipsychotic medication. The possibility of a vaccine‐related autoimmune encephalitis (AE) is tentatively raised.
{"title":"Psychiatric pathology potentially induced by COVID‐19 vaccine","authors":"K. Roberts, Nittu Sidhu, Melanie Russel, Mohammed Abbas","doi":"10.1002/pnp.723","DOIUrl":"https://doi.org/10.1002/pnp.723","url":null,"abstract":"Vaccines are the predominant biological management measure for controlling the COVID‐19 pandemic, and aim to break the chain between disease status and hospitalisation. Unseen or rare side‐effects are being reported via the COVID‐19‐specific Yellow Card reporting site, including mania, psychosis and encephalitis of various subtypes. This article presents a patient displaying a range of psychiatric pathologies that occurred within 10 days of AstraZeneca COVID‐19 vaccination and resolved spontaneously without antipsychotic medication. The possibility of a vaccine‐related autoimmune encephalitis (AE) is tentatively raised.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49464427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Post-COVID-19 acute cognitive syndromes Further to Gaber & Eltemamy’s report of post-COVID-19 aphantasia,1 I suggest that other apparently acute cognitive syndromes are likely to be seen post-COVID-19. A previously healthy 49-year-old woman was referred with a complaint of forgetting following confirmed COVID-19 infection 9 months earlier characterised by cough and fever but not requiring hospitalisation. Prior to this acute illness she reported her memory to be excellent, even for remote details that other family members could not recall. Because of her symptoms, she could no longer pursue her occupation of teaching. Cognitive testing and structural brain imaging disclosed no cause for her symptoms. Inconsistency between self-reported and objective performance was in keeping with a proposed operational definition of functional cognitive disorder (FCD).2 This clinical observation, which I suspect is far from unique, is problematic for metacognitive models of FCD,3 as are other instances of acute onset FCD, such as the dissociative amnesia type,4 which imply sudden rather than gradual change in synaptic neuromodulation. These entities share a clear stressful precipitating event, physical or psychological, the severity of which may be disproportionate to the subsequent cognitive symptoms. The mechanism(s) that underpin acute post-COVID-19 cognitive syndromes such as FCD remain to be determined but might include neurovascular and immunological dysfunction.
{"title":"Post‐COVID‐19 acute cognitive syndromes","authors":"","doi":"10.1002/pnp.731","DOIUrl":"https://doi.org/10.1002/pnp.731","url":null,"abstract":"Post-COVID-19 acute cognitive syndromes Further to Gaber & Eltemamy’s report of post-COVID-19 aphantasia,1 I suggest that other apparently acute cognitive syndromes are likely to be seen post-COVID-19. A previously healthy 49-year-old woman was referred with a complaint of forgetting following confirmed COVID-19 infection 9 months earlier characterised by cough and fever but not requiring hospitalisation. Prior to this acute illness she reported her memory to be excellent, even for remote details that other family members could not recall. Because of her symptoms, she could no longer pursue her occupation of teaching. Cognitive testing and structural brain imaging disclosed no cause for her symptoms. Inconsistency between self-reported and objective performance was in keeping with a proposed operational definition of functional cognitive disorder (FCD).2 This clinical observation, which I suspect is far from unique, is problematic for metacognitive models of FCD,3 as are other instances of acute onset FCD, such as the dissociative amnesia type,4 which imply sudden rather than gradual change in synaptic neuromodulation. These entities share a clear stressful precipitating event, physical or psychological, the severity of which may be disproportionate to the subsequent cognitive symptoms. The mechanism(s) that underpin acute post-COVID-19 cognitive syndromes such as FCD remain to be determined but might include neurovascular and immunological dysfunction.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"25 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42458555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurosyphilis is commonly viewed through the prism of the pre‐penicillin era when parenchymatous neurosyphilis was seen more commonly and presented as general paresis of the insane. In the post‐antibiotic era, meningeal and vascular forms of syphilis are more commonly seen and can present as a stroke. Here, the authors present a case of a 47‐year‐old man with meningovascular neurosyphilis confirmed by CSF serology who presented with cognitive, mood, psychosis, gait changes and sudden‐onset severe vertigo indicative of syphilitic apoplexy.
{"title":"Meningovascular neurosyphilis: cognitive and neuropsychiatric impact","authors":"Madhusudan ( Amod) Mangesh Dalvi, O. Babatola","doi":"10.1002/pnp.726","DOIUrl":"https://doi.org/10.1002/pnp.726","url":null,"abstract":"Neurosyphilis is commonly viewed through the prism of the pre‐penicillin era when parenchymatous neurosyphilis was seen more commonly and presented as general paresis of the insane. In the post‐antibiotic era, meningeal and vascular forms of syphilis are more commonly seen and can present as a stroke. Here, the authors present a case of a 47‐year‐old man with meningovascular neurosyphilis confirmed by CSF serology who presented with cognitive, mood, psychosis, gait changes and sudden‐onset severe vertigo indicative of syphilitic apoplexy.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44784793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson
Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.
{"title":"Digest","authors":"ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson","doi":"10.1002/pnp.252","DOIUrl":"https://doi.org/10.1002/pnp.252","url":null,"abstract":"Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44182203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Gammage, J. Caron, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf
It is unusual for small studies to have much of an impact but an East London team made the national news after paying non‐adherent patients to have their depot injections (Psychiatric Bull 2007;31:4‐7).
{"title":"Digest","authors":"K. Gammage, J. Caron, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf","doi":"10.1002/pnp.4","DOIUrl":"https://doi.org/10.1002/pnp.4","url":null,"abstract":"It is unusual for small studies to have much of an impact but an East London team made the national news after paying non‐adherent patients to have their depot injections (Psychiatric Bull 2007;31:4‐7).","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"11 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41505160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Digest","authors":"ZáNean D. McClain, Jill Pawlowski, Daniel Tindall","doi":"10.1002/pnp.448","DOIUrl":"https://doi.org/10.1002/pnp.448","url":null,"abstract":"Ending summer time increases depression","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"20 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48204711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Gammage, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf
Antidepressant weight gain Anti ‐ depressants are another class of drugs associated with weight gain but a new meta‐analysis of 116 studies identifies some that carry the greatest risk (J Clin Psychiatry 2010;71:1259‐72). Amitriptyline, mirtazapine and paroxetine were associated with the highest risk of weight gain whereas bupropion and acute use of fluoxetine were associated with weight loss. Evidence for other agents was inconclusive.
{"title":"Digest","authors":"K. Gammage, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf","doi":"10.1002/pnp.182","DOIUrl":"https://doi.org/10.1002/pnp.182","url":null,"abstract":"Antidepressant weight gain Anti ‐ depressants are another class of drugs associated with weight gain but a new meta‐analysis of 116 studies identifies some that carry the greatest risk (J Clin Psychiatry 2010;71:1259‐72). Amitriptyline, mirtazapine and paroxetine were associated with the highest risk of weight gain whereas bupropion and acute use of fluoxetine were associated with weight loss. Evidence for other agents was inconclusive.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"14 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49032591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：